| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT07139873 A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) |
Sponsor changed: Dizal (Jiangsu) Pharmaceutical Co., Ltd. -> Dizal Pharmaceuticals |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… | Chronic Lymphocytic Leukemia | Recruiting |
| Phase 3 | |||
| NCT06846671 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic… | CLL | Recruiting |
| NCT07139873 | A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting |
| NCT04666038 | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| Phase 1 | |||
| NCT02787369 | ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL | Recurrent Chronic Lymphoid Leukemia | Active, Not Recruiting |